J.Jpn. Surg. Soc.. 91(9): 1351-1355, 1990
Report on the annual meeting
ADJUVANT THERAPY IN PATIENT WITH BREAST CARCINOMA－DOES RESPONSE PROLONGED SURVIVAL？
|
Department of Surgical Oncology, National Cancer Center Hospital (NCCH), Tokyo, Japan Hiroshi Yamamoto, Takashi Fukutomi, Hidenori Nakai, Hirotoshi Horio, Noriaki Kawano, Masaru Konishi, Takeshi Nanasawa |
The aim of the present report is to evaluate further studies on justification of indications to various aspects of chemotherapy.
As a clinical trial of adjuvant chemotherapy for primary cancer in this study, 435 patients received different regimens of chemotherapeutic drug which were based on the extent of disease since 1983. All patients were subjected to radical mastectomy and no postsurgical radiotherapy were administered. Sixty four patients could not tolerate the complete drug administration and they were excluded in the final analysis.
The 5-year relapse free survivals were estimated for 371 patients treated in 1983 through 1986. Postsurgical use of mild chemotherapy in pT2-3 and pTX with pN0 cancer had not apparently advantage as well as that in pT1pN0 cancer because of a high probability of salvage in node negative.
In the comparative study of combination chemotherapy that contained cyclophosphamide, doxorubicin, methotrexate, and fluorouracil (CAMF) for extensively advanced cancer, much more favorable result was observed in premenopause. Although most final results are still pending, additional endocrine adjuvant treatment (CAMF+tamoxifen) in postmenopause was significantly superior to that with CAMF.
To read the PDF file you will need Adobe Reader installed on your computer.